Cover Image
市場調查報告書

全球疼痛治療藥市場

Global Pain Therapeutics Market to 2023 - Innovative New Products to Address Unmet Need within Chronic Pain and Migraine, and Tackle Opioid Abuse

出版商 GBI Research 商品編碼 524530
出版日期 內容資訊 英文 147 Pages
訂單完成後即時交付
價格
Back to Top
全球疼痛治療藥市場 Global Pain Therapeutics Market to 2023 - Innovative New Products to Address Unmet Need within Chronic Pain and Migraine, and Tackle Opioid Abuse
出版日期: 2017年06月01日 內容資訊: 英文 147 Pages
簡介

本報告提供全球疼痛治療藥市場相關分析,包含主要的上市藥及各醫藥品的收益預測的上市藥形勢概要,疼痛開發平台分析,全球、主要國家市場的詳細的預測分析,主要的產品分類的收益預測,及企業形勢的評估等。

第1章 目錄

第2章 簡介

  • 疾病的概要
  • 症狀
  • 診斷
  • 病理學
  • 流行病學
  • 合併症
  • 併發症
  • 治療

第3章 已上市產品

  • Celebrex (celecoxib) - Pfizer
  • Nucynta (tapentadol) - Depomed
  • Lyrica (pregabalin) - Pfizer
  • Exparel (bupivacaine) - Pacira
  • Voltaren (diclofenac sodium) - Novartis
  • Pennsaid (diclofenac sodium) - Horizon
  • Depakine (valproate sodium) - 第一三共
  • Embeda ER (morphine sulfate + naltrexone) - Pfizer
  • Cymbalta (duloxetine hydrochloride) - Eli Lilly
  • 結論

第4章 開發平台形勢的評估

  • 概要
  • 開發平台開發形勢
  • 開發平台的分子標的
  • 臨床實驗形勢
  • 結論
  • 主要的開發中產品的評估

第5章 多方案的市場預測

  • 整體市場規模
  • 學名藥的滲透
  • 收益預測:各分子標的

第6章 企業分析、定位

  • 收益、市場佔有率分析:各企業
  • 競爭情形
  • 上市藥、開發平台的組合分析

第7章 策略上檢討事項

  • 授權合約
    • 契約:各地區、金額、年度
    • 契約:各適應症
    • 契約:開發階段、各金額
    • 契約:各分子類型、分子標的、金額
    • 授權合約
  • 共同開發契約
    • 契約:各地區、金額、年度
    • 契約:各適應症
    • 契約:各開發階段、金額
    • 契約:各分子類型、分子標的、金額
    • 披露金額的共同開發契約

第8章 附錄

圖表一覽

目錄
Product Code: GBIHC443MR

Executive Summary

Pain can be classified into three main categories. Nociceptive pain involves the activation of nociceptors - neurons specialized in transmitting information regarding pain that signal to the central nervous system (CNS). Inflammatory pain results from tissue damage and activity of immune cells and the third category is pain caused by damage and/or dysfunction of the nervous system.

Pain therapeutics market is forecast to grow from US$19.7 Billion in 2016 to US$28.8 Billion in 2023 at a compound annual growth rate (CAGR) of 5.5%. The US market alone is forecast to be worth US$13.5 Billion in 2023, accounting for 45.2% of the overall pain therapeutics market. Generic products are the main source of market revenue, accounting for over 50% of total market revenue in 2016. This is due mainly to the widespread usage (particularly in the US) of generic opioids, which are far more expensive than other generic analgesics.

There are 817 products in the pain therapeutics pipeline, including 75 for migraine, 118 for inflammatory pain and 255 for neuropathic pain. Some 63% of the pipeline is in the early drug development stages. The most promising drugs within the pipeline include those drugs belonging to the new class of migraine medication, the CGRPR antagonists that have been shown to be an effective preventative therapy for migraines. This class of drugs is forecast to generate an aggregate of US$5 Billion revenue by 2023.

A total of 363 licensing deals for pain therapeutics were completed between 2006 and April 2017, with an aggregate disclosed value of US$11.8 Billion. This highlights pharmaceutical company's interest in investment in analgesics. These deals varied considerably in terms of value, ranging from US$20,000 to US$1.5 Billion. Over 40 deals were valued at less than US$10m, while 19 were valued above US$200m.

The report "Global Pain Therapeutics Market to 2023 - Innovative New Products to Address Unmet Need within Chronic Pain and Migraine, and Tackle Opioid Abuse" provides an introduction to the pain market, including disease epidemiology, symptoms, diagnosis, pathophysiology and co-morbidities and complications.

In depth, this report provides the following analysis -

  • Provides an overview of the landscape for pain marketed products, including product profiles of key marketed products and revenue projections for each of these drugs.
  • Analyses the pain pipeline, detailing, among other parameters, drug distribution by stage of development, molecule type and molecular target, plus an analysis of the key indications in the pipeline: migraine, inflammatory pain and neuropathic pain.
  • Detailed analysis of forecast projections to 2023 on a global level, with forecasts also provided for the US, plus aggregate revenue forecasts of the top five EU markets (the UK, France, Germany, Italy and Spain) and Japan. Revenue forecasts for the major product categories are also provided.
  • Assesses the company landscape in pain, with an analysis of the key players, the types of company involved in this disease cluster, and whether this disease cluster comprises a large proportion of each company's pipeline portfolio and total revenue.

Companies mentioned in this report: Pfizer, Depomed, Pacira, Horizon, Daiichi Sankyo, Novartis, Eli Lilly.

Scope

  • The pain therapeutics market is forecast to reach $28.8 billion in 2023. What are the key market segments driving this growth?
  • The pipeline contains over 800 products. What molecule types and molecular targets are in the pipeline? What are the commercial prospects of promising late stage products?
  • Despite historical high levels of generic drug development, there is a very high proportion of novel drugs in the pipeline. How do failure rates, clinical trial size and clinical trial duration differ by indication and molecular target?
  • Which of the leading companies will have the highest market share by 2023? Which new companies will enter the market?
  • What licensing and co-development deals have occurred within this therapy area since 2006?

Reasons to buy

  • Understand the current clinical and commercial landscape through a comprehensive analysis of innovation in the pain therapeutics market, in the context of the overall pipeline and current market landscape. The report also includes analysis of the deals landscape, including both licensing deals and co-development deals. Key indications covered in detail include neuropathic pain, inflammatory pain (including osteoarthritis pain) and migraine.
  • Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug's mechanism of action.
  • Analyse the pain therapeutics pipeline through a comprehensive review, segmented by stage of development, molecule type and molecular target. This review also provides a detailed look at pain therapeutics clinical trials, to provide an insight into the risk associated with attempting to bring pipeline analgesics to market.
  • Predict growth in market size, with in-depth market forecasting from 2016 to 2023. The forecast will provide an understanding of how epidemiology trends, new drug entries and new drug patent expirations will influence market value.
  • Identify the key pipeline products, with a particular focus on those due to be brought to market in the near future, as well as sales forecasts for these products.
  • Identify the leading companies in the market, in terms of market share and growth. Company analysis determines how dependent the key companies in the market are on revenue derived from pain therapeutic products. In addition, analysis determines the primary factors that will drive market growth for the key companies in the market.
  • Assess the licensing and co-development deal landscape for pain therapies.

1 Table of Contents

1 Table of Contents 4

  • 1.1 List of Tables 6
  • 1.2 List of Figures 6

2 Introduction 9

  • 2.1 Disease Cluster Introduction 9
  • 2.2 Symptoms 9
    • 2.2.1 Migraine 9
    • 2.2.2 Inflammatory pain and neuropathic pain 10
  • 2.3 Diagnosis 10
  • 2.4 Pathophysiology 10
    • 2.4.1 Nociceptive pain transmission 10
    • 2.4.2 Pain modulation in the brain 12
    • 2.4.3 Inflammatory pain 13
    • 2.4.4 Migraine 13
    • 2.4.5 Neuropathic pain 14
  • 2.5 Epidemiology 14
    • 2.5.1 Migraine 14
    • 2.5.2 Inflammatory pain 15
    • 2.5.3 Neuropathic pain 16
  • 2.6 Comorbidities and Complications 17
  • 2.7 Treatment 17
    • 2.7.1 Non-steroidal anti-inflammatory drugs 18
    • 2.7.2 Opioid medications 18
    • 2.7.3 Triptans 20
    • 2.7.4 Other medications 20
    • 2.7.5 Conclusion 21

3 Key Marketed Products 22

  • 3.1 Celebrex (celecoxib) - Pfizer 22
  • 3.2 Nucynta (tapentadol) - Depomed 24
  • 3.3 Lyrica (pregabalin) - Pfizer 26
  • 3.4 Exparel (bupivacaine) - Pacira 27
  • 3.5 Voltaren (diclofenac sodium) - Novartis 28
  • 3.6 Pennsaid (diclofenac sodium) - Horizon 29
  • 3.7 Depakine (valproate sodium) - Daiichi Sankyo 30
  • 3.8 Embeda ER (morphine sulfate + naltrexone) - Pfizer 31
  • 3.9 Cymbalta (duloxetine hydrochloride) - Eli Lilly 32
  • 3.10 Conclusion 34

4 Pipeline Landscape Assessment 35

  • 4.1 Overview 35
  • 4.2 Pipeline Development Landscape 35
  • 4.3 Molecular Targets in the Pipeline 38
  • 4.4 Clinical Trial Landscape 42
    • 4.4.1 Failure Rate by Stage of Development, Indication and Molecule Type 43
    • 4.4.2 Clinical Trial Duration by Stage of Development, Indication, and Molecule Type 46
    • 4.4.3 Clinical Trial Size by Stage of Development, Indication and Molecule Type 48
    • 4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication and Molecule Type 50
  • 4.5 Conclusion 53
  • 4.6 Assessment of Key Pipeline Products 54
    • 4.6.1 HTX-011 - Heron 54
    • 4.6.2 Difelikefalin - Cara 55
    • 4.6.3 Fremanezumab - Teva 56
    • 4.6.4 Eptinezumab - Alder 57
    • 4.6.5 Erenumab - Amgen and Novartis 58
    • 4.6.6 Galcanezumab - Eli Lilly 59
    • 4.6.7 Zilretta - Flexion 60
    • 4.6.8 EMA-401 - Novartis 61
    • 4.6.9 Conclusion 62

5 Multi-scenario Market Forecast to 2022 64

  • 5.1 Overall Market Size 64
  • 5.2 Generic Penetration 67
    • 5.2.1 Generic Opioid Usage 68
  • 5.3 Revenue Forecast by Molecular Target 73
    • 5.3.1 Opioid Receptors 73
    • 5.3.2 Serotonin Receptors 1B and 1D 74
    • 5.3.3 Prostaglandin G/H Synthase (COX) 75
    • 5.3.4 Calcitonin Gene Related Peptide Receptors 76
    • 5.3.5 Multiple Targets 77
    • 5.3.6 Ion Channels 78

6 Company Analysis and Positioning 80

  • 6.1 Revenue and Market Share Analysis by Company 82
    • 6.1.1 Teva - Company Set to Enter the Market and Secure Large Market Share by 2023 86
    • 6.1.2 Pfizer - Key Patent Expiries to Drive Negative Growth 86
    • 6.1.3 Pacira - Company to Secure a Large Market Share despite Small Product Portfolio 87
    • 6.1.4 Novartis - Expansion of Pain Therapeutics Portfolio for the First Time since Voltaren 88
    • 6.1.5 Amgen - Company Set to Enter Pain Market in Early Forecast Period and Achieve Rapid Growth 89
    • 6.1.6 Allergan - Expansion of Product Portfolio to Drive Growth 90
    • 6.1.7 Depomed - Revenue to Rise despite Upcoming Patent Cliff 91
    • 6.1.8 Lilly - Lilly to Expand Position in Market as Patent for Cymbalta Expires 92
  • 6.2 Company Landscape 93
  • 6.3 Marketed and Pipeline Portfolio Analysis 94

7 Strategic Consolidations 97

  • 7.1 Licensing Deals 97
    • 7.1.1 Deals by Region, Value and Year 97
    • 7.1.2 Deals by Indication 98
    • 7.1.3 Deals by Stage of Development and Value 99
    • 7.1.4 Deals by Molecule Type, Molecular Target and Value 100
    • 7.1.5 Licensing Deals with Disclosed Values 101
  • 7.2 Co-development Deals 103
    • 7.2.1 Deals by Region, Value and Year 103
    • 7.2.2 Deals by Indication 104
    • 7.2.3 Deals by Stage of Development and Value 104
    • 7.2.4 Deals by Molecule Type and Value 105
    • 7.2.5 Co-development Deal with Disclosed Values 106

8 Appendix 107

  • 8.1 References 107
  • 8.2 List of Pipeline Products 110
  • 8.3 Table of Epidemiology Forecast 142
  • 8.4 Abbreviations 144
  • 8.5 Methodology 145
    • 8.5.1 Coverage 145
    • 8.5.2 Secondary Research 145
    • 8.5.3 Market Size and Revenue Forecasts 146
    • 8.5.4 Pipeline Analysis 146
    • 8.5.5 Competitive Landscape 147
  • 8.6 Contact Us 147
  • 8.7 Disclaimer 147

1.1 List of Tables

  • Table 1: Pain Therapeutics Market, Global, Approved Indications for Celebrex, 2017 23
  • Table 2: Pain Therapeutics Market, Global, Approved Indications for Nucynta, 2017 24
  • Table 3: Pain Therapeutics Market, Global, Approved Indications for Lyrica, 2017 26
  • Table 4: Pain Therapeutics Market, Global, Approved Indications for Exparel, 2017 27
  • Table 5: Pain Therapeutics Market, Global, Approved Indications for Voltaren, 2017 28
  • Table 6: Pain Therapeutics Market, Global, Approved Indications for Pennsaid, 2017 29
  • Table 7: Pain Therapeutics Market, Global, Approved Indications for Depakine, 2017 30
  • Table 8: Pain Therapeutics Market, Global, Approved Indications for Embeda ER, 2017 31
  • Table 9: Pain Therapeutics Market, Global, Approved Indications for Cymbalta, 2017 33
  • Table 10: Pain Therapeutics Market, Global, Usage of Generics Across Key Indications, 2016 68
  • Table 11: Pain Therapeutics Market, Global, Forecast Revenues by Company, 2016-2023 82
  • Table 12: Pain Therapeutics Market, Global, Pipeline Products, Discovery, 2017 110
  • Table 13: Pain Therapeutics Market, Global, Pipeline Products, Preclinical, 2017 115
  • Table 14: Pain Therapeutics Market, Global, Pipeline Products, IND/CTA-filed, 2017 131
  • Table 15: Pain Therapeutics Market, Global, Pipeline Products, Phase I, 2017 131
  • Table 16: Pain Therapeutics Market, Global, Pipeline Products, Phase II, 2017 135
  • Table 17: Pain Therapeutics Market 138
  • Table 18: Pain Therapeutics Market, Global, Pipeline Products, Pre-registration, 2017 141
  • Table 19: Pain Therapeutics Market, Global, Pipeline Products, Unknown, 2017 141
  • Table 20: Pain therapeutics Market, Epidemiology Patterns for Migraine, 2016-2023 142
  • Table 21: Pain therapeutics Market, Epidemiology Patterns for Post-Herpetic Neuralgia, 2016-2023 143
  • Table 22: Pain therapeutics Market, Epidemiology Patterns for Trigeminal Neuralgia, 2016-2023 143
  • Table 23: Abbreviations 144

1.2 List of Figures

  • Figure 1: Pain Therapeutics Market, Global, Epidemiology Patterns for Migraine, 2016-2023 15
  • Figure 2: Pain Therapeutics Market, Global, Epidemiology Patterns for Post-Herpetic Neuralgia, 2016-2023 16
  • Figure 3: Pain Therapeutics Market, Global, Annual Revenue for Nucynta ($m), 2015-2023 25
  • Figure 4: Pain Therapeutics Market, Global, Annual Revenue for Lyrica ($bn), 2006-2023 27
  • Figure 5: Pain Therapeutics Market, Global, Annual Revenue for Voltaren ($m), 2006-2023 29
  • Figure 6: Pain Therapeutics Market, Global, Annual Revenue for Pennsaid ($m), 2015-2023 30
  • Figure 7: Pain Therapeutics Market, Global, Annual Revenue for Depakine ($m), 2006-2023 31
  • Figure 8: Pain Therapeutics Market, Global, Annual Revenue for Embeda ER ($m), 2016-2023 32
  • Figure 9: Pain Therapeutics Market, Global, Annual Revenue for Cymbalta ($bn), 2006-2023 33
  • Figure 10: Pain Therapeutics Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2017 35
  • Figure 11: Pain Therapeutics Market, Global, Pipeline by Stage of Development, Molecule Type and Program Type, 2017 36
  • Figure 12: Pain Therapeutics Market, Global, Pipeline, Key Indications by Stage of Development, 2017 37
  • Figure 13: Pain Therapeutics Market, Global, Pipeline, Key Indications by Molecule Type, 2017 38
  • Figure 14: Pain Therapeutics Market, Global, Overall Pipeline by Molecular Target, 2017 40
  • Figure 15: Pain Therapeutics Market, Global, Pipeline by Neurotransmission Molecular Target, 2017 41
  • Figure 16: Pain Therapeutics Market, Global, Pipeline for Key Indications by Molecular Target, 2017 42
  • Figure 17: Pain Therapeutics Market, Global, Clinical Trial Failure Rates by Stage of Development and Indication (%), 2006-2017 44
  • Figure 18: Pain Therapeutics Market, Global, Clinical Trial Failure Rates by Stage of Development and Molecular Target (%), 2006-2017 45
  • Figure 19: Pain Therapeutics Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2017 46
  • Figure 20: Pain Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2017 47
  • Figure 21: Pain Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2017 48
  • Figure 22: Pain Therapeutics Market, Global, Clinical Trial Size by Stage of Development (participants), 2006-2017 48
  • Figure 23: Pain Drug Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2017 49
  • Figure 24: Pain Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2017 50
  • Figure 25: Pain Therapeutics Market, Global, Aggregate Clinical Program Size by Stage of Development (participants), 2006-2017 51
  • Figure 26: Pain Therapeutics Market, Global, Aggregate Clinical Program Size by Stage of Development and Indication (participants), 2006-2017 52
  • Figure 27: Pain Therapeutics Market, Global, Aggregate Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2017 53
  • Figure 28: Pain Therapeutics Market, Global, Revenue Forecast for HTX-011 ($m), 2019-2023. 55
  • Figure 29: Pain Therapeutics Market, Global, Revenue Forecast for Difelikefalin ($m), 2018-2023. 56
  • Figure 30: Pain Therapeutics Market, Global, Revenue Forecast for Fremanezumab ($m), 2018-2023 57
  • Figure 31: Pain Therapeutics Market, Global, Revenue Forecast for Eptinezumab ($m), 2018-2023 58
  • Figure 32: Pain Therapeutics Market, Global, Revenue Forecast for Erenumab ($m), 2018-2023 59
  • Figure 33: Pain Therapeutics Market, Global, Revenue Forecast for Galcanezumab ($m), 2018-2023 60
  • Figure 34: Pain Therapeutics Market, Global, Revenue Forecast for Zilretta ($m), 2017-2023 61
  • Figure 35: Pain Therapeutics Market, Global, Revenue Forecast for EMA-401 ($m), 2019-2023 62
  • Figure 36: Pain Therapeutics Market, Global, Market Size ($bn), 2016-2023 64
  • Figure 37: Pain Therapeutics Market, Global, Annual Revenue by Premium and Generic Products ($bn), 2016-2023 67
  • Figure 38: Pain Therapeutics Market, Global, Annual Revenue for Generic Fentanyl ($bn), 2016-2023 69
  • Figure 39: Pain Therapeutics Market, Global, Annual Revenue for Generic Hydromorphone ($m), 2016-2023 70
  • Figure 40: Pain Therapeutics Market, Global, Annual Revenue for Generic Methadone ($m), 2016-2023 71
  • Figure 41: Pain Therapeutics Market, Global, Annual Revenue for Generic Morphine ($bn), 2016-2023 72
  • Figure 42: Pain Therapeutics Market, Global, Annual Revenue for Generic Oxycodone ($bn), 2016-2023 73
  • Figure 43: Pain Therapeutics Market, Global, Annual Revenue Forecast for Drugs Acting on Opioid Receptors ($bn), 2016-2023 74
  • Figure 44: Pain Therapeutics Market, Global, Annual Revenue Forecast for Drugs Acting on Serotonin Receptors 1B and 1D ($m), 2016-2023 75
  • Figure 45: Pain Therapeutics Market, Global, Annual Revenue Forecast for Drug Acting on Prostaglandin Signaling ($bn), 2016-2023 76
  • Figure 46: Pain Therapeutics Market, Global, Annual Revenue Forecast for Drugs Acting on CGRPR ($bn), 2016-2023 77
  • Figure 47: Pain Therapeutics Market, Global, Annual Revenue Forecast for Drugs Acting on Multiple Molecular Targets ($bn), 2016-2023 78
  • Figure 48: Pain Therapeutics Market, Global, Annual Revenue Forecast for Drugs Acting on Ion Channels ($bn), 2016-2023 79
  • Figure 49: Pain Therapeutics Market, Global, Cluster by Growth and Market Share, 2016-2023 80
  • Figure 50: Pain Therapeutics Market, Global, Company Analysis Matrix, 2017 81
  • Figure 51: Pain Therapeutics Market, Global, Forecast Market Share by Company (%), 2016-2023 84
  • Figure 52: Pain Therapeutics Market, Global, Companies by Compound Annual Growth Rate (%), 2016-2023 85
  • Figure 53: Pain Therapeutics Market, Global, Teva Annual Revenue Forecast, 2018-2023 86
  • Figure 54: Pain Therapeutics Market, Global, Pfizer Annual Revenue Forecast, 2016-2023 87
  • Figure 55: Pain Therapeutics Market, Global, Pacira Annual Revenue Forecast, 2016-2023 88
  • Figure 56: Pain Therapeutics Market, Global, Novartis Annual Revenue Forecast, 2016-2023 89
  • Figure 57: Pain Therapeutics Market, Global, Amgen Annual Revenue Forecast, 2018-2023 90
  • Figure 58: Pain Therapeutics Market, Global, Allergan Annual Revenue Forecast, 2016-2023 91
  • Figure 59: Pain Therapeutics Market, Global, Depomed Annual Revenue Forecast, 2016-2023 92
  • Figure 60: Pain Therapeutics Market, Global, Lilly Annual Revenue Forecast, 2016-2023 93
  • Figure 61: Pain Therapeutics Market, Global, High-Activity and Late-Stage Pipeline Developers by Type, 2017 94
  • Figure 62: Pain Therapeutics Market, Global, Pipeline, Overall, High-Activity and Late-Stage Developers by Level of Specialization, 2017 95
  • Figure 63: Pain Therapeutics Market, Global, Proportion of Total Company Revenue Attributed to Pain Therapeutics, 2016-2023 96
  • Figure 64: Pain Therapeutics Market, Global, Licensing Deals by Region, Value and Year, 2006-2016 98
  • Figure 65: Pain Therapeutics Market, Global, Licensing Deals by Indication, 2006-2017 99
  • Figure 66: Pain Therapeutics Market, Global, Licensing Deals by Stage of Development and Value, 2006-2016 100
  • Figure 67: Pain Therapeutics Market, Global, Licensing Deals by Molecule Type, Molecular Target and Aggregate Deal Value, 2006-2017 101
  • Figure 68: Pain Therapeutics Market, Global, Licensing Deals With Disclosed Values, 2006-2017 102
  • Figure 69: Pain Therapeutics Market, Global, Co-development Deals by Region, Value and Year, 2006-2017 103
  • Figure 70: Pain Therapeutics Market, Global, Co-development Deals by Indication and Value, 2006-2017 104
  • Figure 71: Pain Therapeutics Market, Global, Co-development Deals by Stage of Development, 2006-2017 105
  • Figure 72: Pain Therapeutics Market, Global, Co-development Deals by Molecule Type, Mechanism of Action and Aggregate Deal Value, 2006-2016 105
  • Figure 73: Pain Therapeutics Market, Global, Co-development Deals with Disclosed Values, 2006-2017 106
Back to Top